human
intestin
maltas
hma
respons
hydrolysi
nonreduc
end
maltooligosaccharid
hma
becom
import
target
treatment
diabet
studi
epigallocatechin
gallat
egcg
egcg
glucosid
identifi
inhibitor
hma
vitro
assay
ic
respect
lineweaverburk
plot
confirm
egcg
competit
inhibitor
maltos
substrat
hma
inhibit
kinet
constant
k
calcul
dixon
plot
respect
egcg
bound
activ
site
hma
numer
hydrophob
hydrogen
bond
interact
green
tea
attract
signific
attent
scientif
consum
commun
health
benefit
varieti
disord
rang
cancer
weight
loss
epigallocatechin
gallat
egcg
major
catechin
green
tea
account
total
tea
compon
egcg
possess
rang
biolog
medicin
properti
includ
antioxid
anticarcinogen
antiobes
antibacteri
antivir
antienzymat
antimetastasi
effect
latter
effect
direct
matrix
metalloproteinas
mmp
includ
howev
egcg
solubl
water
degrad
easili
aqueou
solut
due
disadvantag
use
egcg
food
drug
cosmet
industri
remain
somewhat
limit
circumv
disadvantag
enzymat
transglycosyl
use
leuconostoc
mesenteroid
glucansucras
appli
modif
egcg
varieti
natur
bioactiv
substanc
improv
function
physicochem
properti
transglycosyl
compound
display
enhanc
function
water
solubl
light
stabil
increas
resist
oxid
less
bitter
tast
small
attract
target
treatment
type
diabet
obes
human
intestin
maltas
hma
ntermin
catalyt
domain
human
intestin
maltaseglucoamylas
mga
respons
activ
hydrolyz
maltos
result
product
glucos
accord
glycosid
hydrolas
gh
classif
scheme
hma
member
studi
examin
inhibit
activ
egcg
egcg
glucosid
hma
express
pichia
pastori
detail
inhibit
mechan
egcg
investig
base
enzym
inhibit
kinet
molecular
dock
studi
use
autodock
materi
p
pastori
express
host
plasmid
purchas
invitrogen
carlsbad
ca
usa
egcg
obtain
sigmaaldrich
st
loui
mo
usa
sephadex
gel
acquir
amersham
bioscienc
uppsala
sweden
hma
protein
mw
da
express
p
pastori
purifi
use
nisepharos
resin
ge
healthcar
buckinghamshir
uk
describ
previous
purifi
sampl
hma
solut
store
c
hma
activ
measur
amount
releas
glucos
maltos
substrat
glucos
oxidaseperoxidas
gop
method
use
glucose
kit
bmi
sungnam
korea
enzymat
reaction
compos
enzym
uml
maltos
variou
concentr
mm
potassium
phosphat
buffer
ph
c
min
reaction
stop
ad
ml
triscl
ph
ml
glucoseoxidas
assay
reagent
reaction
allow
develop
c
h
absorb
measur
nm
determin
amount
glucos
produc
hma
activ
reaction
acceptor
reaction
mediat
l
mesenteroid
glucosyltransferas
purif
use
sephadex
chromatographi
perform
describ
previous
primari
inhibitori
activ
test
compound
determin
measur
remain
activ
hma
concentr
egcg
dissolv
water
mm
stock
solut
enzymat
reaction
compos
enzym
uml
mm
maltos
test
compound
mm
potassium
phosphat
buffer
ph
incub
c
min
control
reaction
carri
follow
inhibit
assay
protocol
except
use
buffer
instead
test
compound
enzymat
activ
measur
glucoseoxidas
assay
describ
sampl
blank
prepar
triplic
inhibitori
concentr
ic
defin
concentr
hma
inhibitor
necessari
reduc
hma
activ
rel
reaction
mixtur
contain
hma
enzym
inhibitor
kinet
paramet
recombin
hma
determin
use
glucoseoxidas
assay
detect
releas
glucos
upon
addit
enzym
increas
maltos
concentr
mm
reaction
time
min
reaction
product
produc
linearli
within
time
frame
method
similar
use
initi
studi
except
multipl
concentr
inhibitor
use
type
inhibit
determin
use
lineweaverburk
plot
calcul
use
sigmaplot
program
sigmastat
san
diego
ca
usa
k
valu
competit
inhibitor
determin
dixon
plot
function
differ
inhibitor
concentr
autodock
dock
softwar
use
perform
autom
molecular
dock
hma
egcg
hma
crystal
structur
pdb
code
inhibitor
acarbos
acr
resolut
prepar
dock
postdock
refin
dock
experi
egcg
water
molecul
inhibitor
acr
locat
activ
site
remov
structur
inform
contain
amino
acid
residu
hma
enzym
use
process
molecular
dock
egcg
hma
describ
previous
hydrogen
interact
egcg
hma
activ
site
pocket
visual
ligplot
softwar
effort
develop
effect
antidiabet
agent
varieti
inhibitor
discov
due
limit
avail
human
search
inhibitor
base
commonli
use
found
bacteria
yeast
plant
anim
tissu
studi
use
human
intestin
maltas
express
p
pastori
purifi
nisepharos
resin
inhibit
assay
egcg
k
v
max
valu
mm
umg
respect
yeast
p
pastori
establish
host
organ
express
heterolog
protein
prokaryot
eukaryot
virus
increas
popular
particular
express
system
attribut
sever
factor
importantli
simplic
techniqu
need
molecular
genet
manipul
p
pastori
similar
saccharomyc
cerevisia
one
wellcharacter
experiment
system
modern
biolog
abil
p
pastori
produc
foreign
protein
high
level
either
intracellularli
extracellularli
capabl
perform
mani
eukaryot
posttransl
modif
glycosyl
disulfid
bond
format
proteolyt
process
avail
express
system
commerci
avail
kit
synthes
use
glucansucras
l
mesenteroid
contain
glycosyl
residu
b
ring
egcg
fig
inhibitori
activ
egcg
toward
recombin
hma
activ
measur
gop
method
compound
egcg
inhibit
hma
activ
respect
tabl
ic
valu
egcg
inhibit
catalyt
activ
hma
calcul
respect
tabl
character
inhibitori
mechan
inhibit
constant
k
egcg
recombin
hma
activ
determin
measur
initi
rate
maltos
hydrolysi
presenc
differ
inhibitor
concentr
lineweaverburk
dixon
plot
use
shown
fig
egcg
exhibit
competit
inhibit
toward
hma
lineweaverburk
plot
versu
result
famili
straight
line
yaxi
intercept
basi
linear
regress
analysi
dixon
plot
fig
inhibitor
constant
k
determin
respect
comparison
acarbos
one
commerci
drug
treatment
diabet
egcg
show
time
time
higher
inhibitori
activ
hma
acarbos
understand
inhibitor
bind
mode
egcg
hma
perform
molecular
dock
simul
hydrogen
bond
interact
compound
activ
site
pocket
hma
egcg
show
strong
bind
activ
site
pocket
hma
free
bind
energi
fig
studi
report
first
time
egcg
competit
inhibit
hma
express
p
pastori
k
valu
respect
egcg
shown
bound
activ
site
hma
dock
simul
use
autodock
softwar
numer
hydrophob
interact
well
hbond
interact
variou
amino
acid
residu
observ
